Kathrine Krokenes L.
- Country
- Norway
- Department
- Department of Neurology
Research Overview
- Comparative Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine, or Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
- A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years
Data & Insights
Has run more than one trial at 4 of 16 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the treatment and research of Multiple Sclerosis (MS), with particular focus on various therapeutic approaches for managing relapsing-remitting MS.
- Aggressive MS Treatment
- Novel Therapeutic Comparisons
- Disease-Modifying Therapies
The research interest extends to evaluating different treatment modalities including monoclonal antibody therapies and hematopoietic stem cell transplantation (HSCT) for MS management.
Immunotherapy
This investigator focuses on advancing immunological treatments for neurological conditions, specifically exploring comparative effectiveness of different immune-modulating therapies.
- B-Cell Targeted Therapies
- Innovative Treatment Protocols
- Clinical Efficacy Assessment
Their work encompasses evaluation of various immunotherapeutic agents and their application in treating active forms of multiple sclerosis.
Clinical Innovation
The investigator's expertise includes conducting non-inferiority studies and comparative analysis of treatment options for neurological disorders.
- Treatment Optimization
- Safety Assessment
- Patient-Focused Outcomes
Their research involves evaluating both established and emerging therapies for aggressive forms of MS, focusing on treatment efficacy and patient safety.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.